Narendranath Epperla, MD, MS, FACP

Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. Co-authored by @JulioChavezMD, @NEpperla, @BachyEmmanuel, @MunshiPashnaMD. Read the full article. brnw.ch/21wWU4b #lymsm #nonhodgkinlymphoma

CONGRESS | #IACH | PRESENTATION Naren Epperla @NEpperla @huntsmancancer provides an overview of innovations in the prognostic assessment of patients with lymphoma. They discuss the prognostic utility of ctDNA by PhaseED-Seq at EOT in patients with 1L DLBCL, the relevance of interim PET after C4 in FL, and the use of prognostic models in EMZL. Follow our live feed for more updates: loom.ly/VEha6BE Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website. #lymphoma #lymsm #MedicalCongress

1/ Why do late-stage cancer patients lose motivation & sink into apathy? 🔥Our new Science paper shows cancer activates a cytokine-sensing brain circuit to lower motivation.Great work by Aelita Zhu @sarahstarosta @Pignatelli_Lab @JanowitzTobias &team!🧵 🔗 doi.org/10.1126/scienc…

🚨 Just out @NatureMedicine! Introducing InflaMix—a point-of-care tool that identifies an #inflammatory 🔥 signature predictive of #CART failure in #lymphoma Led by Sandeep Raj (@SSRaj017) 👏@MSKCancerCenter nature.com/articles/s4159… 🧵Let’s break it down

Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies #mmsm #bmtsm @DrMarcosdelima @NEpperla jhoonline.biomedcentral.com/articles/10.11…

New online! Anthracycline-induced cardiomyopathy: risk prediction, prevention and treatment go.nature.com/40Pt42J

New 3i Investigator Article Alert!! Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma pubmed.ncbi.nlm.nih.gov/39757235/?utm_…

In this statistical editorial, Larry Han, PhD, reviews the concept of left truncation in time-to-event studies. Read the editorial: eviden.cc/3ZiP0mb #ClinicalTrials

Happy to share this new study out in @BloodCancerJnl, coauthored by @NEpperla. nature.com/articles/s4140…

The study shows the safety and long-term efficacy of auto-HCT, even in patients with high-risk cHL who are traditionally considered chemotherapy refractory. ow.ly/HTmq50U5zj6 #lymphoidneoplasia #transplantation

Cardiac considerations with Emerging Cancer Cellular Therapies: ashpublications.org/bloodadvances/… Thanks @BloodAdvances for publishing this work. Excellent work by @MalakMunirMD @ASayedMD @NEpperla #cardioonc #cancer #leukemia #lymphoma

Exciting discovery: CSF flow isn't confined to the brain and spinal cord—it also extends to peripheral nerves! @ScienceMagazine science.org/doi/10.1126/sc… Groundbreaking research from @UFHealth @UF #neurotwitter #neuroscience #AcademicChatter

Multicenter CNS involvement in HGBL NOS @NEpperla: - 160 pts, 7% baseline CNSi - CNSi➡️MYC-R, testicular/female pelvic - no diff in PFS/OS for CNSi vs not (2-yr PFS 53-55%) - 11% CNS relapse at 3 years - mOS 6-7 mos at relapse regardless of CNSi #lymsm ashpublications.org/bloodadvances/…

We are looking forward to working on this more- adding ⬆️ cases & analyses (45-49% vs <45% split was arbitrary but may be relevant). Much more work in this area is needed as these #lymphoma pts are often excluded from clinical trials. @NEpperla @DrRaulCordoba #ASH23 #CardioOnc

#ScienceSaturday Can dietary nutrients help the immune system kill #cancer cells? In this study, researchers screened 255 circulating nutrients for the ability to enhance T cell activity and found that the long-chain fatty acid TVA (Trans-vaccenic acid) could enhance the activity of CD8-positive “killer” T cells against cancer. This impressive work has significant implications for cancer #immunotherapy and beyond. Here’s a link to the full article. nature.com/articles/s4158…

Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study | Blood Advances | American Society of Hematology ashpublications.org/bloodadvances/…

#ASH23 Late breaking abstract 2 The long-awaited SYMPATICO trial Ibr+Ven vs Ibr+pbo RCT in R/R MCL - med PFS 31.9 vs 22.1 months, HR 0.65 p = 0.005 - median OS 44.9 vs 38.6 mo (not significant) ash.confex.com/ash/2023/webpr… h/t @dgermain21 #lymsm

Beyond youth: Understanding CAR T cell fitness in the context of immunological aging - NEW by @jh_noll 🧵sciencedirect.com/science/articl…